Jazz Pharmaceuticals plc — Director's Dealing 2010

Dec 8, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JAZZ PHARMACEUTICALS INC (JAZZ)
CIK: 0001232524
Period of Report: 2010-12-07

Reporting Person: Wissel Janne LT (SVP, Chief Regulatory Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-12-07	Common Stock	S	500	$18.75	Disposed	106721	Direct
2010-12-08	Common Stock	S	59500	$18.38	Disposed	47221	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.36 to $18.41, inclusive.

F2: The reporting person undertakes to provide to Jazz Pharmaceuticals, Inc., any security holder of Jazz Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4.